
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$74.77
+$1.69 · +2.31%
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
前日終値
$74.77
+$1.69 · +2.31%
市場前
$74.81
+$0.04 · +0.05%
10月12日 7:25 ET
日中の時刻はETです。市場データは遅延する場合があります。
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
日中レンジ
現在 $74.77
52週レンジ
現在 $74.77
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
96
大幅な割安
センチメント
66
強気
リスク
43
やや高いリスク
モメンタム
25
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
日中レンジ
現在 $74.77
52週レンジ
現在 $74.77
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 94.67億 USD | 92.56億 USD | 85.44億 USD | 80.8億 USD | 77.76億 USD |
| 売上原価 | 27.94億 USD | 28.6億 USD | 27.1億 USD | 26.04億 USD | 24.64億 USD |
| 粗利益 | 66.73億 USD | 63.96億 USD | 58.34億 USD | 54.76億 USD | 53.12億 USD |
| 研究開発 | 6.98億 USD | 6.86億 USD | 6.14億 USD | 5.39億 USD | 5.08億 USD |
| 販売・一般管理 | 23.78億 USD | 23.18億 USD | 21.51億 USD | 20.09億 USD | 20.01億 USD |
| 営業費用 | 30.76億 USD | 30.04億 USD | 27.65億 USD | 25.48億 USD | 25.09億 USD |
| 受取利息 | 9300万 USD | 1.06億 USD | 1.05億 USD | 5000万 USD | 600万 USD |
| 支払利息 | 2.43億 USD | 2.42億 USD | 2.58億 USD | 2.37億 USD | 2.36億 USD |
| 減価償却費と償却費 | 4.87億 USD | 4.97億 USD | 4.91億 USD | 4.65億 USD | 4.48億 USD |
| 営業利益 | 35.97億 USD | 33.92億 USD | 30.69億 USD | 29.28億 USD | 28.03億 USD |
| 純利益 | 26.73億 USD | 24.86億 USD | 23.44億 USD | 21.14億 USD | 20.37億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$87.33
上昇余地(16.80%)分割調整後の1株当たりの年間現金分配金。
$2.00
2025年(通年)+100.0% 以来 2021
2026年(一部):$1.59
$1.00
2,021
$1.30
2,022
$1.50
2,023
$1.728
2,024
$2.00
2,025
$1.59
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当予定 | 2026年10月30日 | $0.53Quarterly | 2026年10月30日 | 2026年12月1日 |
配当 | 2026年7月20日 | $0.53Quarterly | 2026年7月20日 | 2026年9月1日 |
配当 | 2026年4月20日 | $0.53Quarterly | 2026年4月20日 | 2026年6月2日 |
配当 | 2026年1月20日 | $0.53Quarterly | 2026年1月20日 | 2026年3月3日 |
配当 | 2025年10月31日 | $0.50Quarterly | 2025年10月31日 | 2025年12月2日 |
配当 | 2025年7月18日 | $0.50Quarterly | 2025年7月18日 | 2025年9月3日 |
配当落ち 2026年10月30日
$0.53
Quarterly
2026年10月30日基準 · 支払日 2026年12月1日
配当落ち 2026年7月20日
$0.53
Quarterly
2026年7月20日基準 · 支払日 2026年9月1日
配当落ち 2026年4月20日
$0.53
Quarterly
2026年4月20日基準 · 支払日 2026年6月2日
配当落ち 2026年1月20日
$0.53
Quarterly
2026年1月20日基準 · 支払日 2026年3月3日
配当落ち 2025年10月31日
$0.50
Quarterly
2025年10月31日基準 · 支払日 2025年12月2日
配当落ち 2025年7月18日
$0.50
Quarterly
2025年7月18日基準 · 支払日 2025年9月3日
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T583.63億0.05%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI9.25億0.04%2.3兆 USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO8.59億0.05%1.8兆 USD0.03%$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO6.29億0.28%2264億 USD0.03%$81.14+0.92%
iShares Core S&P 500 ETFIVV4.01億0.05%8964.4億 USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY3.69億0.05%8172億 USD0.09%$778.57+0.60%
Vanguard Morningstar Value ETFVTV2.78億0.11%2624億 USD0.03%$220.59+0.44%
VanEck Morningstar Wide Moat ETFMOAT2.68億2.34%115.3億 USD0.46%$108.74+0.32%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
VanEck Morningstar Wide Moat ETFMOATAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。